{"id":"tunlametinib-plus-vemurafenib","safety":{"commonSideEffects":[{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Vemurafenib is a BRAF V600E inhibitor that directly targets mutated BRAF kinase, while trametinib (tunlametinib) is a MEK1/2 inhibitor that blocks downstream signaling. Together, they provide dual inhibition of the MAPK pathway to overcome resistance and improve efficacy in BRAF-mutant tumors.","oneSentence":"This combination blocks BRAF and MEK signaling in the MAPK pathway to inhibit growth of BRAF-mutant melanoma and other cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:12.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"BRAF V600E-mutant melanoma"},{"name":"BRAF V600E-mutant non-small cell lung cancer"},{"name":"BRAF V600E-mutant colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06008119","phase":"PHASE3","title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Kechow Pharma, Inc.","startDate":"2023-10-25","conditions":"Colorectal Cancer Metastatic","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tunlametinib plus Vemurafenib","genericName":"Tunlametinib plus Vemurafenib","companyName":"Shanghai Kechow Pharma, Inc.","companyId":"shanghai-kechow-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tunlametinib plus Vemurafenib is being studied in a Phase 3 clinical trial for its efficacy and safety in patients with BRAF V600E-mutant metastatic colorectal cancer. Vemurafenib is a small molecule inhibitor of the serine/threonine-protein kinase B-raf.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}